| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |